Late Effects Surveillance System for Sarcoma Patients

Pediatric Blood and Cancer

Volumn 42, Issue 4, 2004, Pages 373-379

  Langer, Thorsten ^a   Stöhr, Wolfgang ^a   Bielack, Stefan ^b   Paulussen, Michael ^b   Treuner, Jörn ^c   Beck, Jörn D ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c OLGAHOSPITAL   (Germany)

Author keywords

Cardiotoxicity; Childhood cancer; Late effects; Long term follow up; Nephrotoxocity; Ototoxicity; Surveillance

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; DRUG WITHDRAWAL; EWING SARCOMA; FEMALE; FOLLOW UP; HEARING IMPAIRMENT; HUMAN; HYPOMAGNESEMIA; KIDNEY TUBULE DISORDER; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OSTEOSARCOMA; OTOTOXICITY; PATIENT MONITORING; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; SYSTOLE;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; CISPLATIN; DOXORUBICIN; FEASIBILITY STUDIES; HEARING DISORDERS; HUMANS; IFOSFAMIDE; INFANT; KIDNEY DISEASES; MAGNESIUM; PHOSPHATES; PILOT PROJECTS; POPULATION SURVEILLANCE; SARCOMA; VENTRICULAR DYSFUNCTION, LEFT;

EID: 1542297790     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.10325     Document Type: Article

References (33)

1. Blatt J, Copeland D, Bleyer W. Late effects of childhood cancer and its treatment. In: Pizzo P, Poplack D, editors. Late effects of childhood cancer and its treatment. Philadelphia: Lippincott-Raven Publishers; 1997. pp 1303-1329.
2. Beck JD, Winkler K, Niethammer D, et al. After-care of children and young adults surviving cancer. Initial recommendations by the late sequelae study group. Klin Padiatr 1995;207:186-192.
3. Hawkins MM, Stevens MC. The long-term survivors. Br Med Bull 1996;52:898-923.
4. Robison LL, Mertens AC, Boice JD, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: A multi-institutional collaborative project. Med Pediatr Oncol 2002;38: 229-239.
5. Langer T, Henze G, Beck J. Basic methods and the developing structures of a late effects surveillance system (LESS) in the long-term follow-up of pediatric cancer patients in Germany. Med Pediatr Oncol 2000;34:348-351.
6. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin N Am 1987;34:571-590.
7. Rossi R, Danzebrink S, Linnenburger K, et al. Assessment of tubular reabsorption of sodium, glucose, phosphate, and amino acids based on spot urine samples. Acta Paediatr 1994;83:1282-1286.
8. Thomas L. Labor und diagnose. Frankfurt/Main: TH-Books Verlagsgesellschaft mbH; 2000.
9. Hausdorf G. Late effects of antrhacycline therapy in childhood: Evaluation and current therapy. In: Bricker J, Green DM, D'Angio GJ, editors. Late effects of antrhacycline therapy in childhood: evaluation and current therapy. New York, Chichester, Brisbane, Toronto, Singapore: Wiley-Liss; 1993. pp 73-85.
10. Lipshultz SE, Easley KA, Orav EJ, et al. Reliability of multicenter pediatric echocardiographic measurements of left ventricular structure and function: The prospective P(2)C(2) HIV study. Circulation 2001;104:310-316.
11. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity [see comments]. Ann Int Med 1996;125:47-58.
12. Steinherz L, Wexler L. The prevantion of anthracycline cardiomyopathy. Prog Pediatr Cardiol 1998;8:97-108.
13. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood [see comments]. N Engl J Med 1991;324:808-815.
14. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266: 1672-1677.
15. Nysom K, Colan SD, Lipshultz SE. Late cardiotoxicity following anthracycline therapy for childhood cancer. Prog Pediatr Cardiol 1998;8:121-138.
16. Meinardi MT, van der Graaf WT, Gietema JA, et al. Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques. Heart 2002;88:81-82.
17. Rossi R, Kleta R, Ehrich JH. Renal involvement in children with malignancies. Pediatr Nephrol 1999;13:153-162.
18. Brock PR, Koliouskas DE, Barratt TM, et al. Partial reversibility of cisplatin nephrotoxicity in children. J Pediatr 1991;118:531-534.
19. English MW, Skinner R, Pearson AD, et al. Dose-related nephrotoxicity of carboplatin in children. Br J Cancer 1999;81: 336-341.
20. Skinner R, Pearson AD, English MW, et al. Cisplatin dose rate as a risk factor for nephrotoxicity in children. Br J Cancer 1998;77: 1677-1682.
21. Cassady JR. Clinical radiation nephropathy. Int J Radiat Oncol Biol Phys 1995;31:1249-1256.
22. Loebstein R, Atanackovic G, Bishai R, et al. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. J Clin Pharmacol 1999;39:454-461.
23. Rossi R, Pleyer J, Schafers P, et al. Development of ifosfamide-induced nephrotoxicity: Prospective follow-up in 75 patients. Med Pediatr Oncol 1999;32:177-182.
24. Ashraf MS, Skinner R, English MW, et al. Late reversibility of chronic ifosfamide-associated nephrotoxicity in a child. Med Pediatr Oncol 1997;28:62-64.
25. Van Gool S, Brock P, Wijndaele G, et al. Reversible hypophosphatemic rickets following ifosfamide treatment [see comments]. Med Pediatr Oncol 1992;20:254-257.
26. Piel IJ, Meyer D, Perlia CP, et al. Effects of cis-diamminedichloroplatinum (NSC-119875) on hearing function in man. Cancer Chemother Rep 1974;58:871-875.
27. Schweitzer VG. Ototoxicity of chemotherapeutic agents. Otolaryngol Clin N Am 1993;26:759-789.
28. Brock PR, Bellman SC, Yeomans EC, et al. Cisplatin ototoxicity in children: A practical grading system. Med Pediatr Oncol 1991; 19:295-300.
29. Ruiz L, Gilden J, Jaffe N, et al. Auditory function in pediatric osteosarcoma patients treated with multiple doses of cis-diamminedichloroplatinum(II). Cancer Res 1989;49:742-744.
30. Amato RJ, Ellerhorst J, Banks M, et al. Carboplatin and ifosfamide and selective consolidation in advanced seminoma. Eur J Cancer 1995;31A:2223-2228.
31. Ameri A, Poisson M, Chauveinc L, et al. Treatment of recurrent malignant supratentorial gliomas with the association of carboplatin and etoposide: A phase II study. J Neurooncol 1997;32:155-160.
32. Namouni F, Doz F, Tanguy ML, et al. High-dose chemotherapy with carboplatin, etoposide, and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: A SFOP and SFGM study. Eur J Cancer 1997;33: 2368-2375.
33. Wandt H, Birkmann J, Denzel T, et al. Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: A phase I/II study in advanced ovarian cancer. Bone Marrow Transplant 1999;23:763-770.